Novocure Shares Rise 17% After FDA Accepts Pre-Market Application
January 18 2024 - 11:10AM
Dow Jones News
By Ben Glickman
Shares of Novocure rose Thursday after U.S. regulators accepted
a pre-market application for the company's lung-cancer therapy.
The stock was up 17% to $14.52 in recent trading. Shares are
down 63% in the last six months.
The Root, Switzerland-based cancer-treatment developer said
Thursday that the U.S. Food and Drug Administration had accepted
its Premarket Approval application for the use of Tumor Treating
Fields therapy to treat non-small cell lung cancer.
Novocure is expecting a decision from the FDA in the second half
of 2024.
The company's trial data, which was submitted to the FDA for
review, tested the safety and effectiveness of TTFields therapy in
combination with standard systemic therapies in treating NSCLC
following progression after receiving platinum-based therapy.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
January 18, 2024 10:55 ET (15:55 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Mar 2024 to Apr 2024
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Apr 2023 to Apr 2024